The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of caphosol oral rinse for prevention of oral mucositis (OM) in sarcoma patients (pts) receiving multicycle doxorubicin-based chemotherapy (CT): Randomized study with cross-over to palifermin for severe OM.
Saroj Vadhan-Raj
Consultant or Advisory Role - EUSA Pharma
Honoraria - Cytogen; EUSA Pharma
Research Funding - EUSA Pharma
Dejka M. Araujo
No relevant relationships to disclose
Jonathan C. Trent
No relevant relationships to disclose
Xiao Zhou
No relevant relationships to disclose
Joseph A. Ludwig
No relevant relationships to disclose
Vinod Ravi
No relevant relationships to disclose
Mark Steven Chambers
No relevant relationships to disclose
Shreyaskumar Patel
Consultant or Advisory Role - Johnson & Johnson; Merck; Novartis; Sanofi
Research Funding - Eisai; Infinity; Johnson & Johnson; PharmaMar
Robert S. Benjamin
No relevant relationships to disclose